Publications by authors named "H Hayasaka"

Dach1 is highly expressed in normal podocytes, but this expression rapidly disappears after podocyte injury. To investigate the role of Dach1 in podocytes in vivo, we analyzed global, podocyte-specific, and inducible Dach1 knockout mice. Global Dach1 knockout (Dach1-/-) mice were assessed immediately after birth because they die within a day.

View Article and Find Full Text PDF

The tumor microenvironment is an extremely complex composed of cancer cells and various non-cancer cells, including lymphatic endothelial cells. Lysophosphatidic acid (LPA) receptors (LPA to LPA) activate a variety of malignant properties in human malignancies. In the present study, we examined the roles of LPA receptor-mediated signaling in biological responses of lymphatic endothelial SVEC4-10 cells induced by hypoxia.

View Article and Find Full Text PDF

The chemokine CCL21 regulates immune and cancer cell migration through its receptor CCR7. The gene encodes the isoform CCL21-Ser, predominantly expressed in the thymic medulla and the secondary lymphoid tissues. This study examined the roles of CCL21-Ser in the antitumor immune response in -knockout (KO) mice.

View Article and Find Full Text PDF

CCL21-Ser, a chemokine encoded by the Ccl21a gene, is constitutively expressed in the thymic epithelial cells and stromal cells of secondary lymphoid organs. It regulates immune cell migration and survival through its receptor CCR7. Herein, using CCL21-Ser-expressing melanoma cells and the Ccl21a-deficient mice, we demonstrated the functional role of cancer cell-derived CCL21-Ser in melanoma growth in vivo.

View Article and Find Full Text PDF
Article Synopsis
  • CCR4 is identified as an important receptor for T-helper 2 (Th2) and Th17 cells and is a potential target for treating atopic dermatitis (AD).
  • In a mouse model of AD induced by MC903 (a TSLP inducer), increased levels of Th2 and Th17-related cytokines and immune cell infiltration were observed, leading to skin lesions.
  • Using a CCR4 inhibitor, Compound 22, showed promise in reducing Th2 and Th17 cells and improving AD-like symptoms, suggesting CCR4 antagonists could help manage allergic reactions in AD.
View Article and Find Full Text PDF